On this page
What it is
A synthetic peptide analogue of alpha-melanocyte-stimulating hormone, acting as a melanocortin receptor agonist. It is a metabolite of melanotan II, developed deliberately for a narrower receptor profile.
How it is proposed to work
Agonism at melanocortin receptors — principally MC4R — in central nervous system pathways involved in sexual desire and arousal. This is a different mechanism from PDE5 inhibitors, which act on vascular smooth muscle, and is why it was pursued for a desire rather than an erectile indication.
Approved medical uses
Hypoactive sexual desire disorder in premenopausal women, in jurisdictions holding an approval. Not approved for erectile dysfunction, not approved in men, and not approved for general libido enhancement.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Randomised controlled trial2019n = 1,267
RECONNECT: two identical phase 3 trials in premenopausal women with HSDD
Finding. Two identical phase 3, randomised, double-blind, placebo-controlled multicentre trials in premenopausal women with hypoactive sexual desire disorder, both coprimary endpoints met. Of 1,267 women randomised, 1,247 formed the safety population and 1,202 the modified intent-to-treat efficacy population. Against placebo, bremelanotide produced statistically significant increases in the Female Sexual Function Index desire domain (study 301: 0.30; study 302: 0.42; integrated 0.35; P < .001) and statistically significant reductions in distress related to low desire on the Female Sexual Distress Scale (study 301: -0.37, P < .001; study 302: -0.29, P = .005; integrated -0.33, P < .001). Nausea, flushing and headache were each reported by at least a tenth of participants in both studies, more often than on placebo.
Limitation. One indication in one narrowly defined population, over 24 weeks: premenopausal women meeting criteria for HSDD, 85.6% of them white and 96.6% recruited at US sites. The endpoints are self-reported questionnaire scores, and the changes are small in absolute terms — about a third of a point on the desire domain — so statistical significance here should not be read as a large clinical effect. Sample size was estimated from simulations on a prior trial rather than from these populations. Authors include employees of the developer and the marketing authorisation holder. Nothing here speaks to use in men, to general libido, or to anything beyond 24 weeks.
- Narrative review2022
Safety review across the clinical development programme
Finding. A review of bremelanotide's safety profile across the clinical development programme, which the authors describe as 3,500 subjects in 43 completed studies, with phase 3 exposure of up to 18 months. In the integrated double-blind portion of the phase 3 studies, the most common adverse events against placebo were nausea (40.0% vs 1.3%), flushing (20.3% vs 1.3%) and headache (11.3% vs 1.9%). Nausea was the most common reason for discontinuation. There were no deaths, and a few subjects experienced serious adverse events. Focal hyperpigmentation was rare when dosed per label but occurred in more than a third of subjects after up to 16 consecutive daily doses. Small, transient but statistically significant blood-pressure increases were seen on ambulatory monitoring, and interactions lowered plasma concentrations of indomethacin and naltrexone. Seventy per cent of the bremelanotide group proceeded to the open-label phase against 87% of those on placebo.
Limitation. A review rather than a trial: the abstract states no search strategy, inclusion criteria or synthesis method, and reports no data of its own. Author affiliations include the developer and the marketing authorisation holder, so this is in substantial part the sponsor's own account of its safety record. It reports no efficacy outcome of any kind, so it supports the safety signals in this dossier and none of the efficacy claim. The authors' own conclusion is that bremelanotide should be used with caution in patients at risk of cardiovascular disease and that blood pressure should be well controlled during treatment.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- CautionEstablished
Nausea is common and dose-related, and was a leading cause of discontinuation in trials.
- CautionEstablished
Transient increases in blood pressure and decreases in heart rate occur after dosing. Labelling carries cardiovascular contraindication considerations for this reason.
- WatchEstablished
Focal hyperpigmentation has been reported, more often with more frequent dosing. The approved use is episodic rather than daily partly because of this.
- SeriousEstablished
Grey-market 'PT-141' is not the approved product. The approval provides no assurance about identity, purity or concentration of material bought outside it.
Known interactions and contraindication considerations
- Blood-pressure effects are relevant alongside antihypertensives and PDE5 inhibitors.
- Labelling carries contraindication considerations for uncontrolled hypertension and known cardiovascular disease.
- Can slow gastric emptying, affecting absorption of concomitant oral medicines.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Approved as of 1 Jun 2026 |
Approval is specific to this indication and population. Use in men is off-label and was not the basis of the approval. |
European Union EMA | Not approved as of 1 Jun 2026 | No EU marketing authorisation for this indication. Verify current status before relying on this. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved. Confirm current CDSCO status before assuming availability. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Desire and arousal, including off-label use in men
What is run
As-needed administration ahead of anticipated activity. The approved use is episodic by design, and community use follows that pattern — but extends it to men, for whom it was not approved and was not the trial population.
Their mechanistic reasoning
That the central MC4R mechanism should work regardless of sex, since the pathway is not sex-specific, and that the approval demonstrates the mechanism is real.
Reported in the community’s own terms. Not our position.
Stacked with
- PDE5 inhibitors—Combined for central plus vascular effect. Blood-pressure interaction applies.
Regimen shape
- Dose
- figure withheld
- Scale
- Milligram-scale, fixed-dose device
- Route
- Subcutaneous autoinjector
- Frequency
- Episodic, with a labelled maximum frequency
- Timing
- Ahead of anticipated activity
- Duration
- Not a course
Our read
The pathway argument is reasonable and the mechanism genuinely is not sex-specific. But an approval establishes benefit and acceptable risk in the population studied — here, premenopausal women with HSDD — and does not transfer automatically. The relevant unknown is not whether the receptor exists in men but whether the benefit-risk balance holds in a group where it was not tested. Using the approved product is nonetheless a materially better decision than substituting melanotan II.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Regarded as genuinely effective by some and as not worth the nausea by others. The discussion is more measured than for most compounds here, probably because it is an approved product with a published trial record people can actually read.
Commonly reported as helping
- Increased desire rather than purely physical response
- Effect described as more gradual and less situational than PDE5 inhibitors
Also reported, when it goes wrong
- Nausea, the dominant complaint and the usual reason for discontinuation
- Headache and flushing
- Cost, frequently cited relative to grey-market alternatives
- Reports of no noticeable effect at all are common
Why these reports can mislead
Desire is subjective and situational, which makes it exceptionally responsive to expectation — the placebo arms in the registration trials showed meaningful improvement too. Off-label reports from men come with no trial comparison at all, so there is no benchmark to judge them against.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Nausea is the leading reason people stop, and it is dose-related.
- Transient blood-pressure rise and heart-rate fall follow dosing — relevant with cardiovascular disease or uncontrolled hypertension.
- Focal hyperpigmentation is reported with more frequent dosing, which is part of why the approved pattern is episodic.
Active clinical trials
No registered trials currently tracked for Bremelanotide.
What remains unknown
The questions that would change our assessment if they were answered.
- Does the safety profile established in premenopausal women transfer to off-label use in men? It has not been established.
- What is the long-term picture with frequent rather than episodic use?
References
- 1.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019.PMID 31599840doi
- 2.Clayton AH, Kingsberg SA, Portman D, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health (Larchmt). 2022.PMID 35147466doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created. Regulatory note written to prevent the approval being read as covering off-label use in men.
Grade of established confirmed rather than changed, and now actually cited. The efficacy claim had been sitting on a placeholder reference, and a citation pass proposed the sponsor's safety review for the slot — a source reporting no efficacy outcome at all, which would have left the grade resting on a paper that does not measure what it grades. Resolved to RECONNECT (Kingsberg 2019), the two phase 3 trials the approval was granted on, with the effect sizes stated so the reader can see how small they are in absolute terms. The safety review was added as its own entry, where it substantiates the safety signals instead of standing in for the trial.
Spotted something wrong? Tell us — we publish corrections.